1.Rolipram, a Phosphodiesterase 4 Inhibitor, Stimulates Inducible cAMP Early Repressor Expression in Osteoblasts.
Eun Sook CHO ; Ja Heon YU ; Mi Sun KIM ; Mijung YIM
Yonsei Medical Journal 2005;46(1):149-154
Phosphodiesterase (PDE) 4 inhibitors have been shown to induce the cAMP-mediated signaling pathway by inhibiting cAMP hydrolysis. This study investigated the effect of a PDE4 inhibitor on the expression of the inducible cAMP early repressor (ICER), which is an endogenous inhibitor of CRE- mediated transcription, in osteoblastic cells. RT-PCR analysis revealed that rolipram, a PDE4 inhibitor, stimulates the ICER mRNA in a dose dependent manner. The induction of ICER mRNA expression by rolipram was suppressed by the inhibitors of protein kinase A (PKA) and p38 MAPK, suggesting the involvement of PKA and p38 MAPK activation in ICER expression by rolipram. It was previously shown that rolipram induced the expression of TNF-related activation-induced cytokine (TRANCE, also known as RANKL, ODF, or OPGL) in osteoblasts. This paper provides evidences that a transcriptional repressor like ICER might modulate TRANCE mRNA expression by rolipram in osteoblasts.
3', 5'-Cyclic-Nucleotide Phosphodiesterase/*antagonists & inhibitors
;
Animals
;
Animals, Outbred Strains
;
Cyclic AMP-Dependent Protein Kinases/metabolism
;
DNA-Binding Proteins/genetics/*metabolism
;
Gene Expression/drug effects
;
Mice
;
Osteoblasts/*drug effects/metabolism
;
Phosphodiesterase Inhibitors/*pharmacology
;
Research Support, Non-U.S. Gov't
;
Rolipram/*pharmacology
;
Transcription Factors/genetics/*metabolism
;
p38 Mitogen-Activated Protein Kinases/metabolism